Profile of darunavir in the management of treatment-experienced HIV patients

Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding...

Full description

Bibliographic Details
Main Authors:	Cameron Wolfe, Charles Hicks
Format:	Article
Language:	English
Published:	Dove Medical Press 2009-09-01
Series:	HIV/AIDS: Research and Palliative Care
Online Access:	http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582

Similar Items

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
by: Michael Neely, et al.
Published: (2009-07-01)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
by: Dobroszycki J, et al.
Published: (2011-09-01)

A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
by: Massimiliano Lanzafame, MD, et al.
Published: (2011-09-01)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
by: Ruxandra-Cristina Marin, et al.
Published: (2021-08-01)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
by: Elżbieta Jabłonowska, et al.
Published: (2019-01-01)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
by: Gregory D. Huhn, et al.
Published: (2019-08-01)

Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure
by: Alberton F, et al.
Published: (2024-04-01)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01)

Virologic and Immunologic Effectiveness at 48 Weeks of Darunavir–Ritonavir-Based Regimens in Treatment-Experienced Persons Living with HIV-1 Infection in Clinical Practice
by: Fernando Martín Biscione MD, PhD, et al.
Published: (2014-01-01)

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)
by: Juan Pasquau, et al.
Published: (2019-02-01)

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
by: Vivek P. Chavda, et al.
Published: (2021-12-01)

Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study
by: Ruxandra-Cristina Marin, et al.
Published: (2023-05-01)

Use of darunavir in HIV-infected women during pregnancy
by: L Iu Afonina, et al.
Published: (2013-11-01)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
by: Putcharoen O, et al.
Published: (2015-10-01)

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
by: Charlotte Charpentier, et al.
Published: (2013-01-01)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
by: Eduardo Arathoon, et al.
Published: (2017-01-01)

Desensitization to darunavir in a pediatric patient
by: Julio César Cambray-Gutiérrez, et al.
Published: (2015-07-01)

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances
by: S. A. Zolotov, et al.
Published: (2021-02-01)

Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment
by: Asit Kumar, et al.
Published: (2023-03-01)

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil
by: Jose E Vidal, et al.

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
by: Miguel A López-Ruz, et al.
Published: (2018-01-01)

Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection
by: G F Moshkovich, et al.
Published: (2014-11-01)

The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
by: Donegan, K, et al.
Published: (2012)

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors
by: Hathaichanok Chuntakaruk, et al.
Published: (2024-02-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
by: Mark J. Naccarato BSc Pharm, et al.
Published: (2018-01-01)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
by: Chow W, et al.
Published: (2020-11-01)

Facial botryomycosis-like pyoderma in an HIV-infected patient: remission after initiation of darunavir and raltegravir
by: Walter de Araujo Eyer-Silva, et al.

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
by: Crutchley RD, et al.
Published: (2016-03-01)

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection
by: Erkki Lathouwers, et al.
Published: (2020-07-01)

Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV
by: Stefan Adrian, et al.
Published: (2020-08-01)

Unique Flap Conformation in an HIV-1 Protease with High-level Darunavir Resistance
by: Masaaki eNakashima, et al.
Published: (2016-02-01)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
by: Osterholzer D
Published: (2013-04-01)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
by: Bruce Rashbaum, et al.
Published: (2019-01-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
by: Claudio Ucciferri, et al.
Published: (2016-07-01)

Correction: Higher plasma drug levels in elderly people living with HIV treated with darunavir.
by: PLOS ONE Staff
Published: (2021-01-01)

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
by: Inés Suárez-García, et al.
Published: (2020-07-01)

The management of treatment-experienced HIV patients (including virologic failure and switches)
by: James Cutrell, et al.
Published: (2020-01-01)

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
by: José Ernesto Vidal, et al.